祥生医疗前三季度营收3.43亿元同比降5.27%，归母净利润9392.05万元同比降4.56%，销售费用同比增长4.03%

Core Insights - Xiangsheng Medical reported a decline in revenue and net profit for the first three quarters of 2025, with revenue at 343 million yuan, down 5.27% year-on-year, and net profit at 93.92 million yuan, down 4.56% year-on-year [1][2] Financial Performance - Basic earnings per share for the reporting period were 0.84 yuan, with a weighted average return on equity of 6.63% [2] - The company's gross margin for the first three quarters was 59.82%, an increase of 0.67 percentage points year-on-year, while the net margin was 27.37%, up 0.20 percentage points year-on-year [2] - In Q3 2025, the gross margin was 58.00%, up 0.86 percentage points year-on-year but down 1.84 percentage points quarter-on-quarter; the net margin was 22.64%, up 7.76 percentage points year-on-year but down 3.26 percentage points quarter-on-quarter [2] Expense Management - Total operating expenses for the period were 105 million yuan, a decrease of 9.26 million yuan year-on-year, with an expense ratio of 30.62%, down 0.94 percentage points year-on-year [2] - Sales expenses increased by 4.03% year-on-year, while management expenses decreased by 11.80%, R&D expenses decreased by 8.40%, and financial expenses decreased by 17.46% [2] Shareholder Dynamics - As of the end of Q3 2025, the total number of shareholders was 6,167, a decrease of 464 from the end of the first half of the year, representing a decline of 7.00% [2] - The average market value of shares held per shareholder increased from 501,400 yuan at the end of the first half to 598,200 yuan, an increase of 19.31% [2] Company Overview - Xiangsheng Medical, established on January 30, 1996, and listed on December 3, 2019, specializes in the research, development, manufacturing, and sales of ultrasound medical imaging equipment [3] - The main revenue sources include ultrasound medical imaging equipment (91.12%), accessories and others (6.49%), technical service fees (2.27%), and other supplementary income (0.12%) [3] - The company operates within the pharmaceutical and biological industry, specifically in medical devices, and is associated with various concepts such as margin financing, high dividends, robotics, artificial intelligence, and overseas expansion [3]